NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against INSYS Therapeutics, Inc. (Nasdaq:INSY) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
On May 9, 2014, media outlets reported that Dr. Gavin Awerbuch, a neurologist who was paid $6.9M from 2009, through Feb. 6, 2014, for his writing prescriptions of INSYS Therapeutics’ cancer pain drug Subsys, was arraigned in federal court in Detroit on charges of health care fraud. Awerbuch is responsible for approximately 20.3% of the Subsys prescribed to Medicare beneficiaries nationwide during this time. This adverse information has caused the price of INSYS stock to fall, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit relating to disclosures about INSYS’ sales and marketing practices. If you purchased INSYS securities prior to May 9, 2014, you may visit the website at http://rosenlegal.com to join the action. You may also contact Phillip Kim, Esq. or Jonathan Horne, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.